Central Nervous System Collaboration and Licensing Deals 2016-2023

$3,995.00

Central Nervous System Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
October 2023
Number of pages
650+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2203

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of central nervous system deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse central nervous system collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

  • Trends in central nervous system dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of central nervous system deal records covering pharmaceutical and biotechnology
  • The leading central nervous system deals by value
  • Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse central nervous system collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in central nervous system dealmaking

 

2.1. Introduction

2.2. Central nervous system partnering over the years     

2.3. Central nervous system partnering by deal type

2.4. Central nervous system partnering by industry sector

2.5. Central nervous system partnering by stage of development

2.6. Central nervous system partnering by technology type

2.7. Central nervous system partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for central nervous system partnering

 

3.1. Introduction

3.2. Disclosed financials terms for central nervous system partnering

3.3. Central nervous system partnering headline values

3.4. Central nervous system deal upfront payments

3.5. Central nervous system deal milestone payments

3.6. Central nervous system royalty rates

 

Chapter 4 – Leading central nervous system deals and dealmakers

 

4.1. Introduction

4.2. Most active in central nervous system partnering

4.3. List of most active dealmakers in central nervous system    

4.4. Top central nervous system deals by value

 

Chapter 5 – Central nervous system contract document directory

                                            

5.1. Introduction

5.2. Central nervous system partnering deals where contract document available

 

Chapter 6 – Central nervous system dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by central nervous system therapeutic target

 

Deal Directory

 

Deal Directory – Central nervous system deals by company A-Z 2016 to 2023

Deal Directory  – Central nervous system deals by technology type 2016 to 2023

 

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Central nervous system partnering since 2016

Figure 2: Central nervous system partnering by deal type since 2016

Figure 3: Central nervous system partnering by industry sector since 2016

Figure 4: Central nervous system partnering by stage of development since 2016

Figure 5: Central nervous system partnering by technology type since 2016

Figure 6: Central nervous system partnering by indication since 2016

Figure 7: Central nervous system deals with a headline value

Figure 8: Central nervous system deals with upfront payment values

Figure 9: Central nervous system deals with milestone payment

Figure 10: Central nervous system deals with royalty rates

Figure 11: Active central nervous system dealmaking activity since 2016

Figure 12: Top central nervous system deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 3E Bioventures Capital, 3SBio, 4B Technologies, 4D Pharma, 4E Therapeutics, 23andMe, A*STAR Agency for Science, Technology and Research, Aachen University, Aardvark Therapeutics, Aarhus University Hospital, Abbott Laboratories, Abbvie, AbCellera Biologics, Abeona Therapeutics, AbFero Pharmaceuticals, ABL Bio, Abuse Deterrent Pharmaceuticals, Abzena, ACADIA Pharmaceuticals, Acasti Pharma, Accelerated Cure Project for MS, Accera Pharmaceuticals, Acella Pharmaceuticals, Acelrx Pharmaceuticals, Acerus, Acetylon Pharmaceuticals, AC Immune, Aclarion, Aclipse Therapeutics, Acorda Therapeutics, ACROBiosystems, Actavis (acquired by Watson), Actelion, Acticor Biotech, Actimed Therapeutics, Acturum Life, Aculys Pharma, Acura Pharmaceuticals, AcuraStem, AdAlta, Adalvo, Adamas Pharmaceuticals, Addex Therapeutics, Adept Neuro, Adhera Therapeutics, Adimune, Adolore Biotherapeutics, Aequus Pharmaceuticals, Aeromics, AffaMed Therapeutics, Affilogic, Affinia Therapeutics, Afraxis, AFT Pharmaceuticals, AgeX Therapeutics, Aguettant, Aichi Medical University, Aidoc, Aiforia Technologies, Akome Biotech, Alamar Biosciences, Albany Molecular Research, Alberta Health Services, Albert Einstein College of Medicine, Alcyone Lifesciences, Alcyone Therapeutics, Alder Biopharmaceuticals, Alector, Alectos Therapeutics, Aleva Neurotherapeutics, Alexion Pharmaceuticals, Alexza Pharmaceuticals, Alfa Wassermann, Algernon Pharmaceuticals, Aliada Therapeutics, Aligning Science Against Parkinson’s, Alkahest, Alkermes, Allay Therapeutics, Allen Institute for Brain Science, Allergan, Alligator Bioscience, Alloy Therapeutics, Alnylam Pharmaceuticals, Alora Pharmaceuticals, Alpha Cognition, ALS Association, AltaML, Altasciences, Altoida, Alto Neuroscience, Alume Biosciences, AlzeCure Pharma, Alzheimer's Drug Discovery Foundation, Amarna Therapeutics, Amathus Therapeutics, Ambiopharm, Ambra Health, American Academy of Neurology, American Association of Neuromuscular & Electrodiagnostic Medicine, American Heart Association, American National Multiple Sclerosis Society, American Speech-Language-Hearing Association, Amgen, Amicus Therapeutics, Amplifybio, Amydis, Amylyx Pharmaceuticals, AnaBios, Andelyn Biosciences, Angelini Pharma, Anima Biotech, Annogen, Annovis Bio, Antibe Therapeutics, Antidote, Apellis Pharmaceuticals, Apic Bio, Aposense, Appello Pharmaceuticals, AppliedVR, APR Applied Pharma Research, AprilBio, APRINOIA Therapeutics, Aptahem, Aptinyx, Aptorum Group, Aqilion, Aquestive Therapeutics, Aquinnah Pharmaceuticals, Aragen Life Sciences, Aratana Therapeutics, Argobio, ARScience Biotherapeutics, Artelo Biosciences, Artiria Medical, Artizan Biosciences, Arvelle Therapeutics, Asahi Intecc, Asahi Kasei, Ashvattha Therapeutics, AskAt, Asklepios Biopharmaceutical, Aspen Neuroscience, Assertio Therapeutics, Association for Frontotemporal Degeneration, Astellas Pharma, Astellas Pharma Europe, Asterias Biotherapeutics, Astex Pharmaceuticals, AstraZeneca, Astrogen, ATAI Life Sciences, Atalanta Therapeutics, Atara Biotherapeutics, Athersys, Athinoula A Martinos Center for Biomedical Imaging, Aucta Pharmaceuticals, Aural Analytics, Aurora Cannabis, Austin Health, Australian Research Council, Autobahn Therapeutics, Autotelic, Avalon Action Alliance, Avanos Medical, Avenue Therapeutics, AveXis, AviadoBio, Avicenna Technology, Axial Biotherapeutics, AXIM Biotechnologies, Axoltis Pharma, AxoSim, Axovant Gene Therapies, Axsome Therapeutics, Axxam, Aziyo Biologics, Bachem, Baergic Bio, Banyan Biomarkers, Barrow Neurological Institute, Baszucki Brain Research Fund, Battelle, Baudry Laboratory, Bayer, Baylor College, B Braun, Beacon Biosignals, Beam Therapeutics, Becton Dickinson, Beijing InnoCare Pharma, Belharra Therapeutics, BenevolentAI, Berg, Beth Israel Deaconess Medical Center, Bexson Biomedical, Bhang, Bial, BIA Separations, Biedermann Motech, Bio-Techne, BioArctic Neuroscience, biOasis Technologies, BioAxone BioSciences, Biobeat, BioCircuit Technologies, BIOCORP, BioDelivery Sciences, Biodextris, Biodirection, Biofourmis, Biogen, Biohaven Pharmaceuticals, BioLamina, BioMarin Pharmaceutical, BioMed X Innovation Center, Biopharmaceuticals Australia, BioQ Pharma, Bioqube Ventures, Biorchestra, BioRestorative Therapies, Bioscience Pharma Partners, BioSyent Pharma, Biotoscana Farma, Biscayne Neurotherapeutics, BL&H, Blackford, Blackfynn, Blackrock Neurotech, BlackThorn Therapeutics, Blinktbi, Bloom Science, BlueRock Therapeutics, Blue Water Biotech, Boehringer Ingelheim, Boston University, Braeburn Pharmaceuticals, Brain and Spine Institute, BRAINBox Solutions, BrainLAB, Brainomix, BrainScope, BrainStorm Cell Therapeutics, Brain Trauma Foundation, Brain Treatment Center San Diego, Brammer Bio, Breakthrough Health, Breath of Life International, BridgeBio Pharma, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brown University, Bruker, BT BeaMedical Technologies, C4 Therapeutics, C4X Discovery, Cactus Semiconductor, Cala Health, California Institute for Biomedical Research, California Institute for Regenerative Medicine, California Institute of Technology, Camargo Pharmaceutical Services, Camarus, CAMP4 Therapeutics, Canadian Armed Forces, Canadian Institutes of Health Research, Canadian Neuromuscular Disease Registry, CannaKids, CannaRoyalty, Cannassure Therapeutics, Cannex Scientific, Canntab Therapeutics, Canon BioMedical, Canopy Growth, Cantabio Pharmaceuticals, Cap Alter Pharma, Capsida Biotherapeutics, Capsigen, Captor Therapeutics, Caraway Therapeutics, Cardiff University, Cardiovascular Solutions of Central Mississippi, CareTaker Medical, Carlsmed, Carmot Therapeutics, Carna BioSciences, Carrum Health, Case Western Reserve University, Casma Therapeutics, Castle Creek Biosciences, Catalent, Catalyst Pharmaceutical Partners, Catalyst Pharmaceuticals, Catholic University Leuven, CavoGene LifeSciences, CBD Solutions, CC Biotechnology, Cedars-Sinai Medical Center, CEITEC, Celeri Health, Celgene, Cell and Gene Therapy Catapult, Cellectricon, Cellenkos, Cellerys, Cellevolve Bio, Celltrion, Cellular Dynamics International, Cellvation, Censo Biotechnologies, CenSyn, Center for Sensorimotor Neural Engineering, Center for the Advancement of Science in Space, Centogene, Centre for Drug Research and Development (CDRD), Centrexion, Centro de Investigación Biomédica en Red de Salud Mental, CerebraCell, Cerecor, CereHealth, Cerevel Therapeutics, CerSci Therapeutics, Certainty Health, Cerveau Technologies, Chamishi Therapeutics, Champalimaud Foundation, Charcot-Marie-Tooth Association, Charite Universitatsmedizin Berlin, Charles River Associates, Charles River Laboratories, ChemDiv, Chemomab Therapeutics, Chiesi Global Rare Diseases, Children's Hospital at Montefiore, Children's Hospital Boston, Children's Minnesota, Children's Research Institute, Christie Medical, Chugai Pharmaceutical, Ciitizen, Cincinnati Children’s Hospital Medical Center, Citizens United for Research in Epilepsy, City of Hope, CK Rizeon, Clearmind Medicine, ClearPoint Neuro, Clearsky Medical Diagnostics, Cleave Therapeutics, Clene Nanomedicine, Cleveland Clinic, Cleveland Diabetes Care, Clexio, Clinical Ink, Clinical Laserthermia Systems (CLS), CliniFusion, Clintrex Research, CMT Research Foundation, CND Life Sciences, Coala Life, Coave Therapeutics, Cobra Biologics, CODA Biotherapeutics, Code Biotherapeutics, Codiak BioSciences, Cognition Therapeutics, CogState, Cohen Veterans Bioscience, Collegium Pharmaceuticals, Columbia University, CombiGene, Complix, Complutense University of Madrid, Concentric Analgesics, Confo Therapeutics, Congenica, Contera Pharma, Convelo Therapeutics, Cook Biotech, Corbin Therapeutics, Corestem, Coronado Biosciences, Cortechs.ai, CorTechs Labs, Cortexyme, Courtagen Life Sciences, Coya Therapeutics, CraniUS, Creative Medical Technologies, CRISPR Therapeutics, Critical Path Institute (C-Path), Crossbeta Biosciences, Crossject, Cumberland Pharmaceuticals, Curebase, CURE Pharmaceutical, Curexo, Currax Pharmaceuticals, Cycle Pharmaceuticals, Cyclica, Cynapsus Therapeutics, Cynergi Health Partners, Cyntar Ventures, Cypralis, Cytocom, Cyxone, D&D Pharmatech, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, DEARhealth, Defense Advanced Research Projects Agency, Defense Health Agency (US), Delix Therapeutics, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, DepoMed, DiagnaMed, Diagnostic Biochips, Diagnostic Robotics, DiaMedica, DiamiR, Dicerna Pharmaceuticals, Digestome Therapeutics, Dixi, doc.ai, Domain Therapeutics, Dong-A Pharmaceutical, Dr. Reddy's Laboratories, Draeger Safety Diagnostics, Dragonfly Therapeutics, DrChrono, DuChemBio, Duke-NUS Graduate Medical School Singapore, Duke University, DyNAbind, Dyno Therapeutics, DZNE German Center for Neurodegenerative Diseases, E-Scape Bio, E-Therapeutics, Eagle Pharmaceuticals, Early Signal Foundation, ECM Therapeutics, EDAP TMS, Editas Medicine, EditForce, eemagine, Egalet, Eikonizo Therapeutics, Eikonoklastes Therapeutics, Eikon Therapeutics, Eisai, Eisai Inc, ELC Group, ElectroCore, Eli Lilly, Elite Pharmaceuticals, EmbodyBio, Emerald Innovations, EmergeOrtho, EMMAC Life Sciences, Emory University, Emulate, Enamine, Encoded Therapeutics, Endo International, Engage Therapeutics, Enigma Biomedical, Ensysce Biosciences, Enterin, Entos Pharmaceuticals, Envisagenics, EpicGenetics, Epilepsy Canada, Epilepsy Foundation (EF), Epilepsy Society, Epygen Biotech, Equilibre BioPharmaceuticals, Erasmus University Medical Center, Essex Bio-Technology, Esteve, ES Therapeutics, EtectRx, Eterna Therapeutics, Ethypharm, Eton Pharmaceuticals, EuMentis Therapeutics, Eureka Eurostars, Eurofarma, Euroimmun, European Innovation Council, European Union, Eversana, EverythingALS Open Innovation Consortium, Evidation Health, Evogen, Evolution Research Group, Evonik Industries, Evotec, Ewopharma, Exagen Diagnostics, Exeltis, Expesicor, Expressive Neuroscience, Eyam Vaccines and Immunotherapeutics, F-Star, Facial Pain Research Foundation, FAR Biotech, Fast Forward, Feinstein Institute for Medical Research, Ferring Pharmaceuticals, FightMND, Find Therapeutics, Fitabase, FitBit, Flexion Therapeutics, Florida Atlantic University Research, Flywheel, Fondazione Telethon, Food and Drug Administration (FDA), Forbius, Forge Biologics, FORMA Therapeutics, Fortress Biotech, Forward Pharma, Fosun Pharmaceutical, Foundation to Fight H-ABC, FreeMind Group, Frequency Therapeutics, Fritz Clinic, FSD Pharma, Fundacion Progreso y Salud, Fuzionaire Diagnostics, Gain Therapeutics, Galapagos, GB Sciences, GE Healthcare, Geisinger Medical Center, Gen, GeneCode, GeneData, GenEdit, GeneDX, Genentech, General Genomics, Genethon, Genetika+, Geneva Foundation, Genmab, Genomics, Genomind, Genpharm, Gensaic, Genzyme, George Washington University, Gilead Sciences, Ginkgo BioWorks, Global Drug Development Centre (GDCC) China, Global Kinetics, GNS Healthcare, Golden Meditech, Goldfinch Bio, GoodRx, Graminex, Graviton Bioscience, Great Ormond Street Hospital (GOSH), Grunenthal, Grupo Juste, GSK, GTx, H1, Hadassah Medical Center, Hainan Sihuan Pharmaceutical, Hainan Sinotau Pharmaceutical, Haisco Pharmaceutical, Halberd, HanAll Pharmaceuticals, Hangzhou Highlightll Pharmaceutical, Happify Health, HAPPYneuron, Harmonic Bionics, Harvard Medical School, Harvard University, Healint, Healios K.K., Healthy Focus, Healx, HeartScore, Helius Medical Technologies, Helmholtz Zentrum Munchen, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Hemostemix, Hennepin County Medical Center, Hennig, Henry Ford Health System, Henry M. Jackson Foundation, Herantis, Hesperos, Hetero Labs, Higgs Boson Health, Hikma Pharmaceuticals, Hitachi, Hoba Therapeutics, Homology Medicines, Honda R&D Americas, Hong Kong Baptist University, HonorHealth, Horizon Discovery, Horizon Europe, Hospital Fondation Adolphe de Rothschild, Hospital for Special Surgery, Hyloris Pharmaceuticals, HypGen, I-mab, IACTA Pharmaceuticals, IAMA Therapeutics, IBM, Icagen, Icahn School of Medicine at Mount Sinai, Icometrix, IDbyDNA, Ideal Medical Solutions, IDIPharma, Idorsia, IIT-Istituto Italiano di Tecnologia, Iktos, Imanova, Imbrium Therapeutics, Imeka, ImmunArray, Immuneering, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Impel NeuroPharma, Imperial College London, Inagene Diagnostics, INBRAIN Neuroelectronics, Incannex Healthcare, Inception Sciences, InCube Labs, Incyte, Indegene Lifesystems, Inexia, Inflazome, InfuTronix Solutions, Inhibikase Therapeutics, INmune Bio, INNERVIA Bioelectronics, Innosuisse, Innovate UK, Inoviem Scientific, Inscopix, Inserm Transfert, InSightec, Insilico Medicine, InSilicoTrials, Insitro, Inspyr Therapeutics, Institute for Research in Biomedicine, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Molecular and Clinical Ophthalmology Basel, Institute of Neurodegenerative Diseases, Insys Therapeutics, Intec Pharma, Integrated Micro-Chromatography Systems, Integrity Implants, IntelGenx, Intellipharmaceutics, Interaxon, International Security Group, International Society of Heart and Lung Transplantation, International Spine Study Group Foundation, Intravacc, Inventia Life Science, Inventum Genetics, Invitae, InVivo Therapeutics, Ionian University, Ionis Pharmaceuticals, IONTAS, Ipsen, IRBM, IRLAB, Iroko Pharmaceuticals, Iron Horse Diagnostics, Irras, iRxReminder, iSchemaView, Ischemix, Isosceles Pharmaceuticals, Israeli National Authority for Technological Innovation, Italian Multiple Sclerosis Society, iX Biopharma, J2H Biotech, JADBio, Jadi Cell, Jan Medical, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, JCR Pharmaceuticals, Jiangsu Aosaikang Pharmaceutical, Jiangsu NHWA Pharmaceutical, Jinzhou Ahon Pharma, Jnana Therapeutics, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson Innovation, Jubilant Biosys, Juno Biomedical, K2M, Kadimastem, Kahn-Sagol-Maccabi, Kairuku, Karolinska Institute, Karuna Therapeutics, Karyopharm Therapeutics, KBI BioPharma, Keck School of Medicine of USC, Keller Army Hospital, KemPharm, Kessler Foundation, Keystone Heart, KeyWise, KIF1A, Kindeva Drug Delivery, Kineta, Kinetic Concepts, Kings College London, Kira Pharmaceuticals, Kissei Pharmaceutical, Kit Check, KK Women’s and Children’s Hospital, Klaria, Knopp Biosciences, Koneksa Health, Koru Medical Systems, Kowa Pharmaceuticals America, Kurve Technology, KVK-Tech, Lacerta Therapeutics, Lancet, Landos Biopharma, Lauren Sciences, Le Bonheur Children's Hospital, Les Laboratoires Servier, Lexicon Pharmaceuticals, LGS Foundation, Liechti Lab, LifeArc, Ligand Pharmaceuticals, Lineage Cell Therapeutics, Link Health, Lipidomics Consulting, Lipidor, LipoCure, Lobe Sciences, Lobsor Pharmaceuticals, Lonza, LoQus23 Therapeutics, Los Altos Pharmaceuticals, LTS Lohmann Therapie-Systeme, Lucid Psycheceuticals, Luciole Medical, Lucy Therapeutics, Ludwig Institute for Cancer Research, Lumosa Therapeutics, Lunatus, Lundbeck, Lundquist Institute, Lund University, Lurie Children's Hospital of Chicago, Luxna Biotech, Lyfebulb, Lysogene, Lysosomal Therapeutics, Maastricht University, Mabylon, Macquarie University, Magic Leap, Magnetic Insight, Mallinckrodt Pharmaceuticals, Mapi Pharma, MapLight Therapeutics, Marinus Pharmaceuticals, Maruho, Masimo, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mass General Brigham, Max-Planck, Mayo Clinic, MC10, McGill University, McMaster University, McNeil Consumer Pharmaceuticals, McQuade Center for Strategic Research and Development, MDimune, Mdoloris Medical Systems, Medical College of Wisconsin Neuroscience Institute, Medical Developments International, Medical iSight, Medical Product Laboratories, Medical Research Council, Medical University of Innsbruck, Medical University South Carolina, MediciNova, Medidata Solutions, Mediolanum, MediPharm Labs, Mediso, MediSynergics, Medolife Rx, Medopad, MedPharm, MedRhythms, Medtronic, MedyMatch, Meiji Seika, MeiraGTx, Melior Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Menarini, MentiNova, Merck and Co, Merck KGaA, Mesoblast, Metabolon, MetaSight Diagnostics, Methodist Hospital Houston, Metrion Biosciences, MetVital, Mi-Helper, Michael J Fox Foundation, Michigan State University, Microsoft, MiNA Therapeutics, MindImmune Therapeutics, MindMaze, Mind Medicine, MindShift Compounds, Mindstrong Health, Minnetronix, Minoryx Therapeutics, Miravo Healthcare, Mirimus, Mission Therapeutics, Mitacs, MitoCanada Foundation, Mitochondrial Innovation Initiative, Mitochon Pharmaceuticals, MitoSense, Mitsubishi Tanabe Pharma, MOBILion Systems, Modag, Moebius Medical, Molecular Health, Molecular Stethoscope, Moleculera Labs, Momenta Pharmaceuticals, Monash University, Montreal Neurological Institute-Hospital, Morphic Therapeutic, Motorpharma, Motric Bio, Mount Sinai Medical Center, Movendo Technology, MRI Interventions, MSD, MThera Pharma, Multiple Sclerosis Society of Canada, Mundipharma, Muscle Activation Technique, Muscular Dystrophy Association, Myeloproliferative Neoplasm Research Consortium, MyHealios, Mylan Laboratories, Mylan Pharmaceuticals, MYND Life Sciences, Myrtelle, Myung In Pharm, n-Lorem Foundation, Nanna Therapeutics, NanoDx, Nanoform, Nanologica, NanoVibronix, NantHealth, National Center for Advancing Translational Sciences (NCATS), National Human Genome Research Institute, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Medical Products, National Organization for Rare Disorders, National Parkinson Foundation (NPF), National Physical Laboratory, National Research Council Canada, National Stem Cell Foundation, National University of Ireland, Galway (NUI Galway), National Yang-Ming University, Nencki Institute, Neogap Therapeutics, Neos Therapeutics, Neotope, Nephron Dx, Nephron Pharmaceuticals, Neptune Technologies & Bioressources, NervGen Pharma, NE Scientific, Nestle Health Science, NetraMark, NeuCyte, Neumentum, Neumora Therapeutics, NeuPath Health, NeurAegis, NeuraLight, Neuraly, Neuramedy, Neuraxpharm, Neurelis, Neuren Pharmaceuticals, NeurExo Sciences, Neurgain Technologies, Neurimmune Therapeutics, Neurim Pharmaceuticals, Neuro3 Therapeutics, Neuro42, Neuro Assessment Systems, NeuroBo Pharmaceuticals, Neurochase, Neurocrine Biosciences, NeuroCycle Therapeutics, NeuroFront, Neurogene, NeuroGenesis, Neurolief, Neurolign Technologies, Neurolixis, NeuroLogica, NeuroMetrix, Neuron23, Neuronasal, Neurona Therapeutics, NeuroNexus, Neuronic, Neuronoff, NeuroOne, NeuroPace, Neuropore Therapies, NeuroScience Associates, NeuroSense Therapeutics, NeuroTracker, NeuroTrauma, Neurotrope BioScience, NeuroVive Pharmaceutical, NeuRx Pharmaceuticals, Neuway Pharma, NeuX Technologies, Newel Health, Newly Institute, Newron Pharmaceuticals, NFANT Labs, NHL Alumni Association, Nico, Nitrome Biosciences, NKGen Biotech, nLife Therapeutics, Noema Pharma, Northeastern University, Northern Biomedical Research, Northern California Institute for Research and Education, North Med, NorthShore University HealthSystem, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Novaremed, Novartis, Noveome Biotherapeutics, Novo Nordisk, Novoron Bioscience, NRG Therapeutics, Nuance Pharma, Nuevolution, Nuformix, Numares, Numerate, NurExone Biologic, Nurosene, Nutra Pharma, Nutriband, NuVasive, Nvidia, Nymirum, NysnoBio, NYU Langone Medical Center, Oakrum Pharma, Oblique Therapeutics, ObvioHealth, Ocular Therapeutix, Oculogica, Ohio State Innovation Foundation, Ohio State University, Oklahoma Medical Research Foundation, Olaris, Olatec Therapeutics, Olea Medical, Oncodesign, Oncotelic, OnDosis, Onegevity, Ono Pharmaceutical, ON Semiconductor, ONWARD Medical, OptiKira, OptiNose, Orchard Therapeutics, Organo Therapeutics, Orion, Orphazyme, OrthoRebirth, Oryzon, Oslo University Hospital, Osmotica Pharmaceuticals, Osseus Fusion Systems, Otsuka, Ovensa, Ovid Therapeutics, OWP Pharmaceuticals, Oxford Biodynamics, Oxford BioMedica, Oxyrane UK, Ozop Energy Solutions, Pacific Biosciences, Pacira Biosciences, Pain Care Labs, PainQx, Panaxia, Panion, Parkinson's Disease Foundation, Parkinson's Institute, Parkinson's Institute and Clinical Center, Parkinson's UK, Parkinsons Disease Foundation, Par Pharmaceutical, Pasithea Therapeutics, Passage Bio, PathMaker Neurosystems, Pathway Rx, Patient-Centered Outcomes Research Institute, PEAR Therapeutics, Peking University, Pennsylvania State University, Pentax, Peptide Logic, PeptiDream, Peptron, Pernix Therapeutics, Pfizer, Pharmaleads, Pharmanest, Pharmanovia, Pharma Scientific Research, PharmaTher, Pharmatronic, Pharma Two B, Pharmazz, PharmEnable, Pharnext, Pheno Therapeutics, Philips, Phoenix PharmaLabs, PhoreMost, PicnicHealth, Pipeline Therapeutics, Planet Green BioTechnology, Plexium, Polpharma, Polyrizon, Poseida Therapeutics, Prana Biotechnology, Praxis Precision Medicines, Prayog Labs, PreCerv, PrecisionLife, Premier Inc, Prevacus, Prevail Therapeutics, PreveCeutical Medical, Primary Peptides, Principia Biopharma, PrinterPrezz, Prize4Life, Procaps, Proclara Biosciences, Progenerative Medical, Progentec Diagnostics, Project ALS, Promenade Software, Prometheus Laboratories, ProMIS Neurosciences, Propella Therapeutics, Prosetta Biosciences, Prothena, Protxx, Proximagen Group, Proximagen Neuroscience, PsychoGenics, Psylo, PTC Therapeutics, Purdue Pharma, Purdue Research Foundation, Purespring Therapeutics, PureTech Health, Q-Gen Cell Therapeutics, Q-State Biosciences, Q30 Innovations, QB3@953, Qiagen, Q Therapeutics, Quadram Institute, Quadrant Biosciences, Quansys Biosciences, Quanterix, Quantiphi, Quartet Medicine, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, Quotient, QurAlis, rAAVen Therapeutics, Rady Children's Institute for Genomic Medicine, Rafa Pharmaceuticals, Rainwater Charitable Foundation, RapidAI, RBC Medical Innovations, RDD Pharma, ReadCoor, Recro Pharma, Recursion, RedHill Biopharma, Regenacy Pharmaceuticals, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regeneus, Regenexx, Regenstrief Institute, Regenxbio, Regulus Therapeutics, Releviate Therapeutics, Relmada Therapeutics, Repertoire Immune Medicines, ReproCell, Reset Therapeutics, RespireRx Pharmaceuticals, restor3d, RetroBrain, Retrotope, Rett Syndrome Research Trust, Revance Therapeutics, Revogenex, ReWalk Robotics, Rgenta Therapeutics, RH Nanopharmacuticals, Rhoshan Pharmaceuticals, Rich Pharmaceuticals, Rigel Pharmaceuticals, Rigshospitalet, RMX Biopharma, Roche, Rodin Therapeutics, RogCon Biosciences, Rosalind Franklin University of Medical Sciences, Rose F Kennedy Intellectual and Developmental Disabilities Research Center, Rosies Base, Roswell Biotechnologies, Royal Philips Electronics, RPRD Diagnostics, Rune Labs, Rutgers Cancer Institute of New Jersey, Rutgers University, RXi Pharmaceuticals, Safe Orthopaedics, Sage Therapeutics, Saint Louis University, Saitama Medical University Hospital, Salus Pharma, Samsung Biologics, Sandoz, Sangamo Therapeutics, Saniona, Sanofi, Santa Clara University, Sarepta Therapeutics, Satsuma Pharmaceuticals, SATT Conectus Alsace, Sawai Pharmaceuticals, Schenker Technologies, Scholar Rock, Schrodinger, Scilex Pharmaceuticals, SciNeuro Pharmaceuticals, Scipher Medicine, SciSparc, Scopus BioPharma, Scribe Therapeutics, Scripps Research Institute, Sean M Healey & AMG Center for ALS, SeaSpine, Seattle Children's Therapeutics, Secarna Pharmaceuticals, Sedor Pharmaceuticals, Seelos Therapeutics, Seikagaku, Selexis, Selonterra, Selvita, Sengenics, Sensome, Senti Biosciences, SeraNovo, SERB Pharmaceuticals, Seurat Therapeutics, SFJ Pharmaceuticals, Shanghai Accurature Diagnostics, Shape Therapeutics, Sharp Edge Labs, Shepherd Center, Shina Systems, Shin Nippon Biomedical Laboratories, Shionogi, Shirley Ryan AbilityLab, Siemens Healthineers, Silo Pharma, SilverCloud Health, Simcere Pharmaceuticals, Sinopia Biosciences, Sio Gene Therapies, SipNose, Sirenas, Sirion Biotech, Sironax, SiteOne Therapeutics, Sites Medical, SKAN Research Trust, SK Biopharmaceuticals, SK Chemicals, Skyhawk Therapeutics, Skyline Vet Pharma, SkyWater Technology, Smithfield BioScience, Society of NeuroInterventional Surgery, Society of Vascular and Interventional Neurology, Soin Neuroscience, Solasia Pharma, Sorrento Therapeutics, Sosei, Sosei Heptares, Sourcia, Spark Therapeutics, Specialised Therapeutics, Spectrum Spine, Sperogenix Therapeutics, Spinal Resources, SpineCraft, Spinogenix, Spotlight Innovation, Stanford University, Stanford University School of Medicine, Starton Therapeutics, Statera Biopharma, Stealth BioTherapeutics, StemoniX, Stevanato, Stimwave Technologies, Stoke Therapeutics, Stony Brook University, Stratus Research Labs, StrideBio, Sumitomo Dainippon Pharma, SunGen, Sunnybrook Research Institute, Sunovion Pharmaceuticals, Sun Pharma Advanced Research Company, Sun Pharmaceutical, SUNY Upstate Medical University, SwanBio Therapeutics, Sway Medical, Swedish Orphan Biovitrum, Swedish Research Council, Swixx Biopharma, Swysh, Synaptogenix, Synlogic, SynPhNe, Synpromics, Syntano Technology Venture, Taiwan Liposome Company, Takeda Pharmaceutical, Target ALS Foundation, Targeted Medical Pharma, Tasly Pharmaceuticals, Tau Consortium, Taysha Gene Therapies, Technology University Dresden, Teijin, Teikoku Pharma USA, Temedica, Tenacia Biotechnology, Tencent Holdings, Terran Biosciences, Tetra Bio-Pharma, Tetragenetics, Teva Pharmaceutical Industries, Tevard Biosciences, Texas Christian University, TFS Corporation, TG Therapeutics, The Consortium of Rheumatology Researchers of North America, The Cure Parkinson's Trust, The Cyprus Institute of Neurology and Genetics, The Multiple Sclerosis Association of America, The New York Stem Cell Foundation, Theradaptive, Thera Neuropharma, Theranica Bio-Electronics, TheraPanacea, Therapeutic Solutions International, Therapix Bio, The Regents of the University of California, Thermo Fisher Scientific, The Silverstein Foundation for Parkinson's, Thomas Jefferson University, TLC BioSciences, Tomahawk Charitable Solutions, TONIX Pharmaceuticals, Toray, Torrey Pines Investment, Toshiba Medical Systems Corporation, Total Brain, Translational Genomics Research Institute, Treeway, Trevena, Trevi Therapeutics, Trillium Therapeutics, Trulieve, Twist Bioscience, twoXAR, TxCell, Tymora Analytical Operations, Ubiquigent, UCB, UGA Biopharma, Uman Diagnostics, Unilife, UniQuest, UniQure, Universidad de Cadiz, Universidad De Sevilla, Universidad de Seville, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of Antwerp, University of Arizona, University of Auckland, University of Barcelona, University of Bath, University of British Columbia, University of Calgary, University of California, Davis, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California Riverside, University of California San Francisco, University of Cambridge, University of Chicago, University of Colorado, University of Copenhagen, University of Edinburgh, University of Florida, University of Glasgow, University of Helsinki, University of Hong Kong, University of Illinois, University of Iowa, University of Kansas, University of Kentucky, University of Konstanz, University of Leeds, University of Lethbridge, University of Marburg, University of Maryland, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts Medical School, University of Memphis, University of Miami, University of Miami Miller School of Medicine, University of Michigan, University of Michigan Medical School, University of Minnesota, University of Montreal, University of Nebraska, University of North Carolina, University of North Texas Health Science Center, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rochester, University of Rochester Medical Center, University of Rome, University of Sheffield, University of Sydney, University of Texas Southwestern Medical Center, University of Toronto, University of Tubingen, University of Utah, University of Washington, University of Wollongong, University of Wyoming, Unlearn, Uppsalagruppen Medical, Uppsala University, Upside Health, US Army, US Army Medical Research and Material Command, US Department of Commerce, Vaccinex, Valence Discovery, VA Medical Center (VAMC), Van Andel Research Institute, Vanderbilt University, Vastrax, Vaxxinity, Vect-Horus, VectorY Therapeutics, Vectura, Veeva Systems, Veltmeyer MD, Ventus Therapeutics, Venus Medtech, Verana Health, Verge Genomics, VeriSIM Life, Vernalis, Versant Ventures, Vertex Pharmaceuticals, VIB, Viela Bio, Vincere Biosciences, Vinnova, Virginia Commonwealth University, Virginia Tech Intellectual Properties, Virpax Pharmaceuticals, VistaGen Therapeutics, Vitruvias Therapeutics, Vividion Therapeutics, Viz.ai, VoxNeuro, Voyager Therapeutics, VU Medical Center, Vyant Bio, Vyripharm, Wake Forest University, Wake Research Associates, Wanbang Biopharmaceuticals, WAVE Life Sciences, WCTE, Weill Cornell Medical College, Weizmann Institute, Whitehead Institute, Willow Biosciences, Winhealth Pharma Group, WinterLight Labs, Winthrop-University Hospital, Wisconsin Health Information Organization, Woolsey Pharmaceuticals, World Stroke Organization, WraSer Pharmaceuticals, Wren Therapeutics, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, Wuxi STA, Wyss Center, Wyss Institute, X-chem, Xenon Pharmaceuticals, Xonovo, XRHealth, Xspire Pharma, XW Laboratories, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yissum Research Development, Yonsei University Severance Hospital, York Instruments, York University, Yposkesi, Yumanity Therapeutics, Zambon, Zelira Therapeutics, Zentiva, Zeta Surgical, Zhittya Genesis Medicine, Zhongze Therapeutics, Zimmer Biomet, Zogenix, Zosano Pharma, ZyVersa Therapeutics, ZZ Biotech

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.